Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
2.

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.

Pineda-Moncusí M, Servitja S, Tusquets I, Diez-Perez A, Rial A, Cos ML, Campodarve I, Rodriguez-Morera J, Garcia-Giralt N, Nogués X.

Breast Cancer Res Treat. 2019 Aug;177(1):53-60. doi: 10.1007/s10549-019-05289-7. Epub 2019 May 24.

PMID:
31127467
3.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
4.

SEOM clinical guidelines in early stage breast cancer (2018).

Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E.

Clin Transl Oncol. 2019 Jan;21(1):18-30. doi: 10.1007/s12094-018-1973-6. Epub 2018 Nov 15.

5.

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens.

Blancas I, Aguirre E, Morales S, Gonzálvez ML, Servitja S, Díaz N, Del Barco S, Barnadas A, Margelí M, García Carbonero I, Llombart A.

Clin Transl Oncol. 2019 Apr;21(4):459-466. doi: 10.1007/s12094-018-1946-9. Epub 2018 Oct 6.

PMID:
30293232
6.

Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women.

Pineda-Moncusí M, Garcia-Perez MA, Rial A, Casamayor G, Cos ML, Servitja S, Tusquets I, Diez-Perez A, Cano A, Garcia-Giralt N, Nogues X.

Maturitas. 2018 Oct;116:83-88. doi: 10.1016/j.maturitas.2018.07.015. Epub 2018 Jul 29.

PMID:
30244785
7.

Bone health evaluation one year after aromatase inhibitors completion.

Pineda-Moncusí M, Servitja S, Casamayor G, Cos ML, Rial A, Rodriguez-Morera J, Tusquets I, Diez-Perez A, Garcia-Giralt N, Nogués X.

Bone. 2018 Dec;117:54-59. doi: 10.1016/j.bone.2018.09.010. Epub 2018 Sep 14.

PMID:
30223134
8.

Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain.

Román M, Caicoya M, Espinàs J, Sala M, Torá-Rocamora I, Quinta MJ, Vernet M, Saladié F, Romero A, Sánchez M, Baré M, Vidal C, Servitja S, Natal C, Corominas J, Ferrer J, Rodríguez-Arana A, Castells X; BELE Project study group.

Breast J. 2018 Jul;24(4):509-518. doi: 10.1111/tbj.13003. Epub 2018 Mar 8.

PMID:
29517151
9.

Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain.

Esteban I, Vilaró M, Adrover E, Angulo A, Carrasco E, Gadea N, Sánchez A, Ocaña T, Llort G, Jover R, Cubiella J, Servitja S, Herráiz M, Cid L, Martínez S, Oruezábal-Moreno MJ, Garau I, Khorrami S, Herreros-de-Tejada A, Morales R, Cano JM, Serrano R, López-Ceballos MH, González-Santiago S, Juan-Fita MJ, Alonso-Cerezo C, Casas A, Graña B, Teulé A, Alba E, Antón A, Guillén-Ponce C, Sánchez-Heras AB, Alés-Martínez JE, Brunet J, Balaguer F, Balmaña J.

Psychooncology. 2018 Jun;27(6):1530-1537. doi: 10.1002/pon.4686. Epub 2018 Mar 26.

PMID:
29498768
10.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

11.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

12.

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.

Posso M, Corominas JM, Serrano L, Román M, Torá-Rocamora I, Domingo L, Romero A, Quintana MJ, Vernet-Tomas M, Baré M, Vidal C, Sánchez M, Saladié F, Natal C, Ferrer J, Servitja S, Sala M, Castells X; BELE Study Group.

Cancer Med. 2017 Jun;6(6):1482-1489. doi: 10.1002/cam4.1080. Epub 2017 May 4.

13.

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.

Dierssen-Sotos T, Gómez-Acebo I, de Pedro M, Pérez-Gómez B, Servitja S, Moreno V, Amiano P, Fernandez-Villa T, Barricarte A, Tardon A, Diaz-Santos M, Peiro-Perez R, Marcos-Gragera R, Lope V, Gracia-Lavedan E, Alonso MH, Michelena-Echeveste MJ, Garcia-Palomo A, Guevara M, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, Llorca J.

BMC Cancer. 2016 Aug 20;16(1):660. doi: 10.1186/s12885-016-2692-4.

14.

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.

Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P.

Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12.

15.

Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.

Martínez-Jañez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P.

Breast Care (Basel). 2016 Apr;11(2):133-8. doi: 10.1159/000443601. Epub 2016 Feb 8.

16.

AI-related BMD variation in actual practice conditions: A prospective cohort study.

Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.

Endocr Relat Cancer. 2016 Apr;23(4):303-12. doi: 10.1530/ERC-16-0025. Epub 2016 Feb 24.

PMID:
26911377
17.

SEOM clinical guidelines in early-stage breast cancer 2015.

Garcia-Saenz JA, Bermejo B, Estevez LG, Palomo AG, Gonzalez-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez CA, Ciruelos E.

Clin Transl Oncol. 2015 Dec;17(12):939-45. doi: 10.1007/s12094-015-1427-3. Epub 2015 Oct 26.

18.

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.

Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, Nogues X, Tusquets I.

Ther Adv Med Oncol. 2015 Sep;7(5):291-6. doi: 10.1177/1758834015598536. Review.

19.

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.

Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, Díez-Pérez A, Grinberg D, Tusquets I, Nogués X.

J Mol Endocrinol. 2015 Aug;55(1):69-79. doi: 10.1530/JME-15-0079. Epub 2015 Jun 24.

PMID:
26108486
20.

Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program.

Castells X, Domingo L, Corominas JM, Torá-Rocamora I, Quintana MJ, Baré M, Vidal C, Natal C, Sánchez M, Saladié F, Ferrer J, Vernet M, Servitja S, Rodríguez-Arana A, Roman M, Espinàs JA, Sala M.

Breast Cancer Res Treat. 2015 Jan;149(1):237-44. doi: 10.1007/s10549-014-3208-z. Epub 2014 Dec 13.

21.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
22.

[Development and validation of an algorithm to identify cancer recurrences from hospital data bases].

Manzanares-Laya S, Burón A, Murta-Nascimento C, Servitja S, Castells X, Macià F.

Rev Calid Asist. 2014 Jul-Aug;29(4):237-44. doi: 10.1016/j.cali.2014.05.004. Epub 2014 Jun 28. Spanish.

PMID:
24985242
23.

An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.

Conde-Estévez D, Tusquets I, Servitja S, Martínez-García M, Salas E, Albanell J.

Anticancer Drugs. 2014 Oct;25(9):992-7. doi: 10.1097/CAD.0000000000000130. Review.

PMID:
24892723
24.

Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.

Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17.

25.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F.

Oncotarget. 2014 Jan 15;5(1):196-210.

26.

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.

Garcia-Giralt N, Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogués X.

Breast Cancer Res Treat. 2013 Jul;140(2):385-95. doi: 10.1007/s10549-013-2638-3. Epub 2013 Jul 19.

PMID:
23868189
27.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A.

J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3.

PMID:
23733779
28.

Factors affecting 5- and 10-year survival of women with breast cancer: an analysis based on a public general hospital in Barcelona.

Macià F, Porta M, Murta-Nascimento C, Servitja S, Guxens M, Burón A, Tusquets I, Albanell J, Castells X.

Cancer Epidemiol. 2012 Dec;36(6):554-9. doi: 10.1016/j.canep.2012.07.003. Epub 2012 Jul 31.

PMID:
22854422
29.

Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.

Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S, García E, González I, de Miguel MJ, Pérez Q, Milena A, Ruiz A, Barnadas A.

Clin Transl Oncol. 2012 Jun;14(6):413-22. doi: 10.1007/s12094-012-0818-y. Review.

PMID:
22634529
30.

Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers.

Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M.

Eur J Cancer Prev. 2013 Jan;22(1):21-8. doi: 10.1097/CEJ.0b013e328354d324.

PMID:
22584215
31.

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.

Prieto-Alhambra D, Servitja S, Javaid MK, Garrigós L, Arden NK, Cooper C, Albanell J, Tusquets I, Diez-Perez A, Nogues X.

Breast Cancer Res Treat. 2012 Jun;133(3):1159-67. doi: 10.1007/s10549-012-2013-9. Epub 2012 Mar 21.

PMID:
22434523
32.

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.

Servitja S, Ramos M, Gil M, Sánchez-Rovira P, Vázquez-Estevez S, Virizuela JA, García-Estevez L, Velasco A, Tusquets I.

Anticancer Drugs. 2012 Feb;23(2):239-46. doi: 10.1097/CAD.0b013e32834e2fe4.

PMID:
22112931
33.

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.

Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I.

Breast. 2012 Feb;21(1):95-101. doi: 10.1016/j.breast.2011.09.001. Epub 2011 Sep 15.

PMID:
21924904
34.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.

Ann Oncol. 2012 May;23(5):1156-64. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9.

PMID:
21908496
35.

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.

Guerrero A, Servitja S, Rodríguez-Lescure A, Calvo L, del Barco S, Quintanar MT, Juárez JI, Gayo J, Llombart A, Tusquets I.

Anticancer Drugs. 2011 Mar;22(3):283-9. doi: 10.1097/CAD.0b013e3283425c55.

PMID:
21150776
36.

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J.

J Clin Pathol. 2011 Feb;64(2):130-5. doi: 10.1136/jcp.2010.082966. Epub 2010 Dec 8.

PMID:
21148141
37.

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.

Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-García M, Diez-Perez A, Albanell J, Tusquets I, Nogues X.

Breast Cancer Res Treat. 2011 Feb;125(3):869-78. doi: 10.1007/s10549-010-1075-9. Epub 2010 Jul 28.

PMID:
20665105
38.

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.

Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I.

Maturitas. 2010 Jul;66(3):291-7. doi: 10.1016/j.maturitas.2010.03.012. Epub 2010 Apr 15.

PMID:
20399042
39.

Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain.

Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, Macià F, Quintana MJ, Albanell J, Castells X.

Cancer Causes Control. 2010 Aug;21(8):1155-64. doi: 10.1007/s10552-010-9541-6. Epub 2010 Mar 28.

PMID:
20349271
40.

Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.

Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J.

Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5.

Supplemental Content

Loading ...
Support Center